Again buys Genomatica to build end-to-end biomanufacturing platform
What's the deal? Technology company Again has acquired industrial biotechnology firm Genomatica (Geno), combining computational biotechnology, bioprocess engineering, and industrial-scale manufacturing. Financial terms were not disclosed.
What each side brings: Again develops multi-feedstock production pathways for making industrial products from different raw materials. Geno has focused on biotechnology processes that produce chemicals and materials from renewable feedstocks.
What's the endgame? The acquisition extends Again's reach across the full development process — from pathway discovery and molecule design to scale-up and commercial manufacturing. Together, the companies span discovery, process development, and industrial-scale production.
Why it matters: Central to the deal is Geno's AI and computational biotechnology platform, plus its patent portfolio and data covering experimental research, structural analysis, and scale-up. Again plans to fold these into its own platform to improve modelling and shorten development cycles for new products.
What's the plan? The combined company will run several commercial models: licensing its technology, co-developing production pathways with industrial partners, and manufacturing products through existing and planned assets.
"By integrating that with our scale-up platform and novel feedstock technologies, we are building the world's leading biomanufacturing platform," said Max Kufner, chief executive officer of Again.
The signal: The deal reflects a broader push to pair AI-driven molecule discovery with the hard part — translating algorithms into commercial-scale production. As Kufner put it, "algorithms are only as good as their ability to translate into real-world, commercial-scale execution."
Read more: Tech.eu
Image credit: myfuture.com
